Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TRIP11
REST API REST API
Homo sapiens
TRIP11 is differentially expressed in 289 experiments: 152 organism parts: skin, bone marrow, ... (150 more);, 204 disease states: normal, breast carcinoma, ... (202 more);, 76 cell types 391 cell lines 35 compound treatments and 78 other conditions.
Synonyms Trip230, CEV14, GMAP-210
Orthologs MLP2 (Saccharomyces cerevisiae)   MLP1 (Saccharomyces cerevisiae)   TRIP11 (Gallus gallus)   Trip11 (Mus musculus)   trip11 (Danio rerio)   TRIP11 (Bos taurus)   Tig (Drosophila melanogaster)   Trip11 (Rattus norvegicus)   NP_001006807.1 (Xenopus laevis)   trip11 (Xenopus laevis)   TRIP11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, protein targeting to Golgi, cytoskeleton, cytoplasm, membrane, Golgi apparatus, transcription from RNA polymerase II promoter, intracellular membrane-bounded organelle, transcription coactivator activity, nucleus
InterPro Term GRIP
UniProt Accession Q15643, F5H1Z0
Gene-Disease Assocation ACHONDROGENESIS, TYPE IA; ACG1A
Search EB-eye ENSG00000100815
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
H1437
2
E-GEOD-16194, E-MTAB-62
BT-474
2
E-GEOD-3529, E-GEOD-5823
DU145
2
E-GEOD-17482, E-GEOD-20089
HepG2
2
E-GEOD-21154, E-GEOD-7307
MOLT4
2
E-MTAB-37, E-MTAB-62
385 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (42 experiments)

Factor Value U/D Experiments
stromal cell
1
2
E-GEOD-1460, E-GEOD-3998, E-MEXP-2034
embryonic stem cell
1
E-MEXP-930
mesendoderm/endoderm progenitor cell
1
E-MEXP-930
articular cartilage
1
E-MEXP-2488
leydig cell
1
E-MTAB-25
immortalised T lymphocytes
1
E-GEOD-13909
70 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (59 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
cervical carcinoma
2
E-MTAB-37, E-GEOD-5823
chronic myelogenous leukemia
2
E-MTAB-62, E-MTAB-37
pancreatic carcinoma
2
E-MTAB-37, E-MEXP-1121
prostate cancer
2
E-MTAB-62, E-GEOD-6919
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
198 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-GEOD-5099, ... (20 experiments)

Factor Value U/D Experiments
placebo
1
E-MEXP-1327
FCCP
1
1
E-MEXP-2285
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
heregulin
1
E-GEOD-6462
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
29 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
53
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-TABM-868, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-5824, ... (8 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-12293, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.438 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM